Page 11 - Lupin

Lupin gets EIR from USFDA for its manufacturing plant in Nagpur

The company's shares surged 4.14% to Rs 820.40 after they received the inspection report (EIR) from the US drug regulator

Lupin gets EIR from USFDA for Florida-based inhalation research centre

The Center at Coral Springs, Florida, focuses on research and development of respiratory products for the treatment of asthma, chronic obstructive pulmonary diseases and other respiratory ailments.

Nifty outlook and top stock recommendations by CapitalVia: Buy Lupin, ITC

Stock of Lupin is showing sign of oversold on RSI indicator. Breakout from the level of 638 would lead stock to witness more upward movement.

Stock calls by Sameet Chavan of Angel Broking: Buy Sun TV Network, Lupin

Once the banking stocks start chipping in, the Nifty is likely to reclaim 12,220 - 12,300 in coming weeks

Lupin Q3 net loss widens to Rs 835 crore, sales drop to Rs 3,716 crore

Consolidated sales of the company stood at Rs 3,716 crore for the quarter under consideration

Market Ahead, February 3: Top factors that could guide markets this week

On the corporate earnings front, Bharti Airtel, Lupin, Sun Pharma, and Mahindra & Mahindra are among the major companies scheduled to declare their October-December results this week

USFDA classifies inspection of Lupin unit as 'Official Action Indicated'

Official Action Indicated means 'objectionable conditions were found and regulatory administrative sanctions by FDA are indicated' during inspections

Lupin dips 2% as USFDA classifies Tarapur unit as Official Action Indicated

The company, however, said it does not believe that this inspection classification will have an impact on disruption of supplies or the existing revenues from operations of this facility.

Nifty view & two stocks that Sameet Chavan of Angel Broking is bullish on

Stock calls and Outlook on Nifty by Mr. Sameet Chavan, Chief Analyst- Technical & Derivatives, Angel Broking Ltd.

Exposure to US market causing constant FDA scrutiny for big drug firms

Dr Reddy's was in the news for falling short of expectations during routine audits conducted by the US drug regulator

Lupin launches generic drug in US for treatment, prevention of hypokalemia

The company had earlier received approval for the product from the United States Food and Drug Administration

Nifty outlook and stock pick by Angel Broking: Buy Persistent, Lupin

Stock calls and Outlook on Nifty by Mr. Sameet Chavan, Chief Analyst- Technical & Derivatives, Angel Broking Ltd.

Anti-tuberculosis drug market continues to shrink for private firms

Lupin, the largest player in India's anti-TB market, too admitted that in anti-TB segment, the focus on branded business has declined in the past few years

Uncertainty over US biz growth keeps Street cautious on Lupin stock

A strong product pipeline and growth in India and emerging markets are positives, but regulatory hurdles, delayed drug approvals in the US could hurt prospects

We are growing our biosimilars capacity six-fold: Lupin MD Nilesh D Gupta

We were into APIs in the US and we started finished products, said Nilesh D Gupta

Active pharmaceutical ingredients focus helps drug firms offset slowdown

Besides captive consumption, the company also supplies APIs to external customers across international markets

Lupin recalls more than 18,000 bottles of antibiotic drug in US market

The drug, cefdinir for oral suspension, has been manufactured by Lupin's Mandideep manufacturing facility in central India

Lupin's Goa plant may face regulatory action, says USFDA after inspection

Lupin said in a regulatory filing that the US health regulator had made two observations following the inspection and had classified the inspection as Official Action Indicated

Lupin slips 5% as USFDA classifies Goa facility's inspection as OAI

The USFDA stated that Goa facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed.

Lupin's Q4 disappoints on soft India sales, higher tax and interest costs

Analysts remain neutral on the stock given limited growth visibility in US, regulatory and lawsuit overhangs